Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Research ArticleAccepted Article

Correlation of a Modified Disease Activity Score with the Validated Original Disease Activity Score in Patients with Juvenile Dermatomyositis

Hayyah Clairman, Saunya Dover, Kristi Whitney, Jo-Anne Marcuz, Audrey Bell-Peter and Brian M. Feldman
The Journal of Rheumatology March 2020, jrheum.191255; DOI: https://doi.org/10.3899/jrheum.191255
Hayyah Clairman
From Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Canada; Division of Rheumatology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada; Department of Rehabilitation, The Hospital for Sick Children, Toronto, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. Address correspondence to Dr. Brian M. Feldman, 555 University Avenue, Toronto, Ontario, M5G 1X8 CANADA. Email: brian.feldman@sickkids.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saunya Dover
From Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Canada; Division of Rheumatology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada; Department of Rehabilitation, The Hospital for Sick Children, Toronto, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. Address correspondence to Dr. Brian M. Feldman, 555 University Avenue, Toronto, Ontario, M5G 1X8 CANADA. Email: brian.feldman@sickkids.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristi Whitney
From Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Canada; Division of Rheumatology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada; Department of Rehabilitation, The Hospital for Sick Children, Toronto, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. Address correspondence to Dr. Brian M. Feldman, 555 University Avenue, Toronto, Ontario, M5G 1X8 CANADA. Email: brian.feldman@sickkids.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jo-Anne Marcuz
From Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Canada; Division of Rheumatology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada; Department of Rehabilitation, The Hospital for Sick Children, Toronto, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. Address correspondence to Dr. Brian M. Feldman, 555 University Avenue, Toronto, Ontario, M5G 1X8 CANADA. Email: brian.feldman@sickkids.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Audrey Bell-Peter
From Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Canada; Division of Rheumatology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada; Department of Rehabilitation, The Hospital for Sick Children, Toronto, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. Address correspondence to Dr. Brian M. Feldman, 555 University Avenue, Toronto, Ontario, M5G 1X8 CANADA. Email: brian.feldman@sickkids.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian M. Feldman
From Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Canada; Division of Rheumatology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada; Department of Rehabilitation, The Hospital for Sick Children, Toronto, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. Address correspondence to Dr. Brian M. Feldman, 555 University Avenue, Toronto, Ontario, M5G 1X8 CANADA. Email: brian.feldman@sickkids.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
Next
Loading

Abstract

Objective Juvenile dermatomyositis (JDM) is a rare disease in children that is treatable, but patients may suffer from long-term effects of the disease. Clinical trials are needed to find better treatments for affected patients. Among validated tools for evaluating disease activity clinically is the disease activity score (DAS), but it is not routinely collected in all clinics. We developed a modified DAS (DASmod) which can be scored using data routinely collected by our clinical staff, and has been used in previous studies. This study’s objective was to determine if our DASmod correlates with the validated DAS in patients with JDM.

Methods In this study, we used DASmod (scored 0-12) and DAS scores (scored 0-20) for patients with JDM in our clinic. We analysed the correlation between the DASmod and the validated DAS.

Results For 51 patients seen in our JDM clinic, the median (IQR) DASmod score was 2.0 (0, 4.0) and the median (IQR) DAS score was 3.0 (0, 5.5). Scores on the two tools were highly positively correlated (r = 0.94, p < 0.001, 95% CI [0.89, 0.96]). The linear regression was significant (R2 = 0.88, F (1, 49) = 357.60, p < 0.001) and in this dataset, the tools can be used interchangeably with the regression equation: DAS score = -0.26 + 1.5*DASmod.

Conclusion If the regression equation from this dataset is successfully tested against future datasets, then further research collaborations between centres that collect different data related to disease activity in children with JDM will be facilitated.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Next
Back to top

In this issue

The Journal of Rheumatology
Vol. 48, Issue 1
1 Jan 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Correlation of a Modified Disease Activity Score with the Validated Original Disease Activity Score in Patients with Juvenile Dermatomyositis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Accepted manuscript
Correlation of a Modified Disease Activity Score with the Validated Original Disease Activity Score in Patients with Juvenile Dermatomyositis
Hayyah Clairman, Saunya Dover, Kristi Whitney, Jo-Anne Marcuz, Audrey Bell-Peter, Brian M. Feldman
The Journal of Rheumatology Mar 2020, jrheum.191255; DOI: 10.3899/jrheum.191255

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Accepted manuscript
Correlation of a Modified Disease Activity Score with the Validated Original Disease Activity Score in Patients with Juvenile Dermatomyositis
Hayyah Clairman, Saunya Dover, Kristi Whitney, Jo-Anne Marcuz, Audrey Bell-Peter, Brian M. Feldman
The Journal of Rheumatology Mar 2020, jrheum.191255; DOI: 10.3899/jrheum.191255
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Relation of NSAID, DMARD and TNF-inhibitors for Ankylosing Spondylitis and Psoriatic Arthritis to Risk of Total Hip and Knee Arthroplasty
  • Use of Hydroxychloroquine And Risk of Heart Failure in Patients With Rheumatoid Arthritis
  • Safety and Efficacy of Poseltinib, Bruton’s Tyrosine Kinase-Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase-2 Study
Show more Accepted Article

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire